Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences (Nasdaq: CSTL) has published a new study showing their DecisionDx-Melanoma test surpasses both AJCC staging and CP-GEP in identifying low-risk melanoma patients. The test achieved a 2.8% sentinel lymph node positivity rate, significantly below the NCCN guidelines' 5% threshold for avoiding sentinel lymph node biopsy (SLNB) surgery.
The study, published in Cancer Diagnosis & Prognosis, analyzed T1-T2 melanoma tumors across multiple validation studies. While patients classified as low risk by CP-GEP showed a 6.2% SLN positivity rate, DecisionDx-Melanoma demonstrated superior performance at 2.8%. This improvement is particularly significant as over 90% of T1-T2 tumor patients who undergo SLNB receive negative results.
The findings support using DecisionDx-Melanoma to guide SLNB decisions, especially for patients with thin tumors where surgical complications may outweigh benefits. The test provides personalized risk assessment for sentinel lymph node positivity and recurrence, enabling more informed melanoma management decisions.
Castle Biosciences (Nasdaq: CSTL) has announced reaching a significant milestone of over 200,000 DecisionDx-Melanoma clinical test orders. The DecisionDx-Melanoma is a 31-gene expression profile test designed for patients with stage I-III cutaneous melanoma.
The test provides personalized risk assessment by analyzing tumor biology and clinicopathologic features to predict recurrence risk, metastasis potential, and sentinel lymph node positivity. Its clinical value is validated by more than 50 peer-reviewed publications and studies involving over 10,000 patient samples, demonstrating association with improved patient survival.
Castle Biosciences (CSTL) presented new research data at the AACR Annual Meeting 2025 focusing on their DecisionDx tests for melanoma patients. The study of DecisionDx-Melanoma (n=1,661) showed that patients with Class 2B results had significantly higher distant metastasis rates compared to Class 1A across multiple sites: CNS (7.4% vs 0.9%), lung (7.4% vs 1.2%), liver (4.5% vs 0.6%), and bone (3.0% vs 0.8%).
Additionally, research on DecisionDx-UM for uveal melanoma revealed that among 79 patients, 72% were classified as low risk (Class 1) and 28% as high risk for metastasis. The study identified significant protein differences in aqueous humor samples between risk classes (N=386, p0.0001), potentially enabling earlier detection and intervention for uveal melanocytic tumors.
Castle Biosciences (CSTL) has scheduled the release of its first quarter 2025 financial results for Monday, May 5, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results.
The live webcast will be accessible through the company's investor relations website and a dedicated event link. Participants can join via phone by dialing 1 833 470 1428 from the United States using access code 040892. International dial-in numbers are available. A Q&A session will follow management's presentation, and a webcast replay will be provided after the call.
Castle Biosciences (CSTL) is strengthening its commitment to esophageal cancer awareness through partnerships with key organizations during Esophageal Cancer Awareness Month in April 2025. The company is collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS), and The Gut Doctor Podcast.
With esophageal cancer's five-year survival rate at only 20%, early detection is crucial. The company's TissueCypher® test helps identify which Barrett's esophagus patients among the 1.5 million U.S. cases are at risk of progressing to cancer, affecting approximately 0.5% of cases.
Key initiatives include:
- ECAN partnership featuring digital media campaigns and awareness kits
- Special episode on AFS's All Fore Guts! podcast about screening importance
- Collaboration with The Gut Doctor Podcast discussing risk factors and treatment
Castle Biosciences (Nasdaq: CSTL) has secured the Top Workplaces USA Award for the fourth consecutive year, ranking 30th among 358 U.S. companies with 500-999 employees. The recognition, awarded by Energage and USA Today, is based on employee feedback through a third-party engagement survey.
Key highlights from the survey include:
- 95% participation rate (above 56% benchmark)
- 85% employee engagement score (exceeding 74% industry average)
- Assessment based on 15 culture drivers indicating high performance
The company, which specializes in innovative health tests for patient care, was selected from over 42,000 invited organizations. The achievement underscores Castle's commitment to maintaining a people-first culture and fostering an environment that promotes innovation and employee empowerment.
Castle Biosciences (CSTL) has published significant results from their DECIDE study regarding their DecisionDx-Melanoma test in melanoma patients. The study demonstrates the test's ability to accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity who can safely avoid sentinel lymph node biopsy (SLNB) surgery.
Key findings show that DecisionDx-Melanoma influenced 85% of SLNB decisions. In patients with low-risk test results (Class 1A), none who underwent SLNB had positive nodes (0/35 patients). Notably, all patients with Class 1A results remained recurrence-free after two years of median follow-up, regardless of whether they underwent SLNB.
The study validates the test's alignment with National Comprehensive Cancer Network guidelines, which recommend avoiding SLNB when SLN positivity risk is below 5%. This helps reduce unnecessary surgical procedures, complications, and associated costs while focusing surgical interventions on higher-risk patients.